Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.41 |
| ▸ | DRD1 | P21728 | 3/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | DRD5 | P21918 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 5/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22337067 | 1.00 | NFE2L2 (0.41) | NFE2L2DRD2DRD3DRD1DRD4 | |
| SCHEMBL17195668 | 0.77 | CA12 (0.50) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL6478831 | 0.73 | KMT2A (0.48) | HPGDKMT2AMEN1 | |
| SCHEMBL9957718 | 0.72 | DRD2 (0.60) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL21226952 | 0.72 | CXCR2 (0.45) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL21609715 | 0.71 | HPGD (0.52) | NFE2L2DRD2DRD3HPGDKMT2A | |
| SCHEMBL21609724 | 0.71 | HDAC3 (0.41) | NFE2L2HPGDKMT2AMEN1 | |
| SCHEMBL21609714 | 0.71 | HPGD (0.52) | NFE2L2DRD2DRD3HPGDKMT2A | |
| SCHEMBL22337074 | 0.71 | HDAC3 (0.41) | NFE2L2HPGDKMT2AMEN1 | |
| SCHEMBL7256334 | 0.71 | CA2 (0.36) | NFE2L2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519173-B2 | Process for the removal and return of a catalyst to a liquid phase medium | PHOSPHONICS LTD (GB) | 2019-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519173-B2 | Process for the removal and return of a catalyst to a liquid phase medium | GRB2, GFRA2, LIFR | NFE2L2 363/4885DRD2 1003/4885DRD3 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.